NSCLC is not one market. Histology, stage and biomarker cut it into segments with different competitors, and only a minority of patients are fully tested before first-line therapy begins.
Segmentation comes before any competitive question. Histology splits the population first, stage splits it again, and actionable biomarkers split it a third time into groups with entirely different treatment algorithms and competitive sets. A plan built on headline incidence rather than on the segment an asset actually treats will overstate the opportunity several times over.
Testing, not efficacy, is the rate-limiting step. Only a minority of US patients receive the full guideline-recommended biomarker panel before first-line therapy starts, which caps the reachable population for every targeted agent regardless of label. It is a pathway problem rather than a clinical one: who orders the panel, whether the tissue sample is adequate, and whether results return before treatment begins.
In first-line immunotherapy the assay requirements do more competitive work than the efficacy data. The approved regimens divide into distinct testing tiers, one requiring a specific assay at a defined expression threshold, another carrying no threshold, another requiring a different assay entirely. Which assay a site runs, and which a payer reimburses, gates the regimen before any efficacy argument is heard. All of these agents are physician-administered and reimbursed through the medical benefit rather than the pharmacy benefit, which changes who carries acquisition risk and which utilisation controls apply.
AXLRx NSCLC reports resolve the segmentation, map where the pathway loses patients before treatment, and set out the channel economics.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
US NSCLC segments by histology and biomarker before it segments by drug. This maps where patients are actually diagnosed and tested, and where the gap between diagnosis and treatment costs them.
Incidence-to-eligible NSCLC funnel by cohort with sourced conversion assumptions and a share waterfall.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%. But PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.
NSCLC is a specialist, buy-and-bill oncology market, not a mass-reach primary-care one. A concentrated medical-oncology prescriber base, biomarker-gated prescribing, and infused immuno-oncology under Medicare Part B dictate a small, account-based key-account and MSL field model.
Pembrolizumab holds an estimated 52% of first-line NSCLC on five years of precedent. Payers evaluate every new IO or targeted asset against KEYNOTE, CheckMate and IMpower coverage policy, not against a fresh trial design.
By histology, then stage, then biomarker, and the order matters. An estimated 229,410 new lung cancer diagnoses are expected in the US in 2026, roughly 85% of them non-small cell. Fifty-one percent present at distant stage against 24% localized. Biomarker then splits the population again: EGFR in about 17 to 19%, ALK in 3 to 9% depending on the population studied, KRAS G12C in 10 to 13%, and high PD-L1 expression in 21 to 27% of driver-negative disease. A commercial plan built on the headline incidence figure rather than on the segment an asset actually treats will overstate the opportunity several times over.
Because a patient who is not tested is not addressable, whatever the label says. Only 46% of US patients receive all five guideline-recommended biomarker tests before first-line therapy begins. That single figure caps the reachable population for every targeted agent in the market, and it is a pathway problem rather than a clinical one: who orders the panel, whether tissue is adequate, and whether results return before treatment starts. Expanding testing penetration moves more volume than a marginal efficacy advantage does.
They divide the field into three distinct testing tiers, and the tier decides the practical comparator set. Pembrolizumab monotherapy requires 22C3 PD-L1 immunohistochemistry at a 50% tumour proportion score. Nivolumab plus ipilimumab carries no PD-L1 threshold at all. Atezolizumab requires a separate SP142 assay. Durvalumab's approved use is Stage III consolidation after chemoradiotherapy, which sits outside the first-line contest entirely. Which assay a site runs, and which a payer will reimburse, therefore gates the regimen before any efficacy argument is heard.
All four approved first-line agents are physician-administered biologics reimbursed through Medicare Part B buy-and-bill at ASP plus a percentage, not through the Part D pharmacy benefit. That routes the economics through the site of care rather than a pharmacy benefit manager's formulary, changes who carries the acquisition risk, and puts a different set of utilisation controls in play. An access plan written for a pharmacy-benefit product does not transfer.
The analysis behind the questions above: a segmentation that resolves histology, stage and biomarker into the pool an asset can actually treat; a read on where the diagnosis-to-treatment pathway loses patients before first-line therapy; the assay and prior-authorisation requirements that gate each competing regimen; and the Part B channel economics that determine how the product is bought. Each is scoped to your asset and delivered as a sourced report, an editable model, or an executive readout.